FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suites
Covered in this story
Call it yourself
No calls on $AVT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Avnet →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.